<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV style="font-size: 10pt">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>


<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt"><B>Date of Report (Date of earliest event reported): March 4, 2009</B>

<P align="center">

<P align="center" style="font-size: 24pt"><B>KREIDO BIOFUELS, INC.<BR></B>
<FONT style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>Nevada</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>333-130606</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>20-3240178</B></TD>
</TR>
<TR valign="top">
    <TD>(State or other Jurisdiction of Incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD>(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD>(IRS Employer Identification No.)</TD>
</TR>
</TABLE>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>1070 Flynn Road<BR>Camarillo, California<BR></B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>93012</B></TD>
</TR>
<TR valign="top">
    <TD>(Address of Principal Executive Offices)</TD>
    <TD>&nbsp;</TD>
    <TD>(Zip Code)</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: <B>(805) 389-3499</B>


<TABLE border="0" width="30%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR>
    <TD nowrap style="border-bottom: 1px solid #000000"><B>Not applicable<BR></B></TD>
</TR>
<TR>
    <TD nowrap>(Former name or former address if changed since last report.)</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

<P align="left" style="font-size: 10pt">
<FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<P>
<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;1.02 Termination of Material Definitive Agreement.</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">On March&nbsp;5, 2009, in connection with the sale of assets discussed under Item&nbsp;2.01 below, Kreido
Biofuels, Inc. (the &#147;Company&#148;) effected a Separation Agreement with Philip Lichtenberger, Senior
Vice President and Chief Operating Officer of the Company, pursuant to which his Employment
Agreement dated April&nbsp;4, 2007 and his employment with the Company and its wholly owned subsidiaries
were terminated. Under the Separation Agreement, the Company paid Mr.&nbsp;Lichtenberger severance pay
of $237,500 which was provided for in his Employment Agreement, and he and the Company released and
discharged each other from all known and contingent liabilities and obligation. The Company
retired stock options held by Mr.&nbsp;Lichtenberger for nominal consideration.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;2.01 Completion of Acquisition or Disposition of Assets.</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">On
March&nbsp;5, 2009, the Company and Four Rivers BioEnergy, Inc.
(&#147;Four Rivers&#148;) consummated the transactions contemplated by their
previously disclosed Asset Purchase Agreement, dated as of January&nbsp;28, 2009. The Company sold to
Four Rivers its STT<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> reactors and STT<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> technology as well as its modular biodiesel production plant
equipment and related assets. The assets sold constituted substantially all of the assets of the
Company. The aggregate consideration paid by Four Rivers to the Company consisted of $2,792,000 in
cash, the assumption of certain of purchase orders and contracts, 1,200,000 shares of Four Rivers&#146;
common stock and a warrant to purchase 200,000 shares of Four Rivers&#146; common stock at an exercise
price of $8.00 per share with an expiration date of March&nbsp;5, 2014. The warrant provides for
anti-dilution adjustment in limited circumstances and piggyback registration rights with respect to
the underlying shares of common stock.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Of the 1,200,000 shares of Four Rivers common stock issued to the Company, 300,000 will be held in
escrow solely to cover the exercise of certain Company warrants that are exercisable until January
12, 2012, which if not exercised will cause the shares to be returned to Four Rivers.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">The shares of Four Rivers common stock and the Four Rivers warrant (including the underlying
shares) are subject to a 360&nbsp;day holding requirement, after which the shares may be sold or
distributed.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">The Asset Purchase Agreement and the transactions therein were approved by the holders of a
majority of the issued and outstanding shares of Company common stock at a duly noticed
stockholders meeting held on March&nbsp;4, 2009.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers</B>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">At a duly noticed stockholders meeting held on March&nbsp;4, 2009, the following directors were
re-elected to the Company&#146;s Board of Directors: G. A. Ben Binninger, Betsy Wood Knapp, David
Mandel and David Nazarian.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">As discussed under Item&nbsp;1.02 above, on March&nbsp;5, 2009, in connection with the sale of assets
discussed under Item&nbsp;2.01 above, the Company effected a Separation Agreement with Philip
Lichtenberger, Senior Vice President and Chief Operating Officer of the Company, pursuant to which
his Employment Agreement dated April&nbsp;4, 2007 and his employment with the Company and its wholly
owned subsidiaries were terminated.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits.</B>
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Exhibits</DIV></TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="77%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center" colspan="3">Exhibit</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">Number</TD>
</TR>


<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">99.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Separation
Agreement dated as of February&nbsp;27, 2009 by and among
Kreido Biofuels, Inc., Kreido Laboratories and Philip Lichtenberger</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">99.2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Asset Purchase Agreement dated as of January&nbsp;28, 2009 by and among
Four Rivers BioEnergy, Inc., The Four Rivers BioEnergy Company, Inc.,
Kreido Biofuels, Inc. and Kreido Laboratories (incorporate by
reference to Exhibit&nbsp;99.2 to Current Report on Form&nbsp;8-K filed by the
Company on February&nbsp;23, 2009, File No.&nbsp;333-130606)</DIV></TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><U><B>Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995</B></U>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Information included in this Form 8-K may contain forward-looking statements within the meaning of
Section&nbsp;27A of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;) and Section&nbsp;21E of the
Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). This information may involve
known and unknown risks, uncertainties and other factors which may cause the Company&#146;s actual
results, performance or achievements to be materially different from future results, performance or
achievements expressed or implied by any forward-looking statements. Forward-looking statements,
which involve assumptions and describe the Company&#146;s future plans, strategies and expectations, are
generally identifiable by use of the words &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;anticipate,&#148;
&#147;estimate,&#148; &#147;believe,&#148; &#147;intend&#148; or &#147;project&#148; or the negative of these words or other variations on
these words or comparable terminology. These forward-looking statements are based on assumptions
that may be incorrect, and there can be no assurance that any projections included in these
forward-looking statements will come to pass. The Company&#146;s actual results could differ materially
from those expressed or implied by the forward-looking statements as a result of various factors.
Except as required by applicable laws, the Company undertakes no obligation to update publicly any
forward-looking statements for any reason, even if new information becomes available or other
events occur in the future.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>SIGNATURES</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>KREIDO BIOFUELS, INC.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Dated: March 5, 2009&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">G.A. Ben Binninger /s/
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">G.A. Ben Binninger&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Its: Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>EXHIBIT INDEX</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="77%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center" colspan="3">Exhibit</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">Number</TD>
</TR>


<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">99.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Separation Agreement dated as of February&nbsp;27, 2009 by and among
Kreido Biofuels, Inc., Kreido Laboratories and Philip Lichtenberger</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">99.2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Asset Purchase Agreement dated as of January&nbsp;28, 2009 by and among
Four Rivers BioEnergy, Inc., The Four Rivers BioEnergy Company, Inc.,
Kreido Biofuels, Inc. and Kreido Laboratories (incorporate by
reference to Exhibit&nbsp;99.2 to Current Report on Form&nbsp;8-K filed by the
Company on February&nbsp;23, 2009, File No.&nbsp;333-130606)</DIV></TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "c82146e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 18181}]
{"company-data": {"conformed-name": "Kreido Biofuels, Inc.", "cik": "0001342219", "assigned-sic": "2860", "irs-number": "203240178", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "333-130606", "film-number": "09662263"}, "business-address": {"street1": "1140 AVENIDA ACASO", "city": "CAMARILLO", "state": "CA", "zip": "93012", "phone": "805-389-3499"}, "mail-address": {"street1": "1140 AVENIDA ACASO", "city": "CAMARILLO", "state": "CA", "zip": "93012"}, "former-company": {"former-conformed-name": "Gemwood Productions, Inc.", "date-changed": "20051024"}}
Form 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 4, 2009
KREIDO BIOFUELS, INC.
(Exact name of registrant as specified in its charter)
Nevada
333-130606
20-3240178
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
1070 Flynn Road
Camarillo, California
93012
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including area code:
(805) 389-3499
Not applicable
(Former name or former address if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.02 Termination of Material Definitive Agreement.
On March 5, 2009, in connection with the sale of assets discussed under Item 2.01 below, Kreido
Biofuels, Inc. (the "Company") effected a Separation Agreement with Philip Lichtenberger, Senior
Vice President and Chief Operating Officer of the Company, pursuant to which his Employment
Agreement dated April 4, 2007 and his employment with the Company and its wholly owned subsidiaries
were terminated. Under the Separation Agreement, the Company paid Mr. Lichtenberger severance pay
of $237,500 which was provided for in his Employment Agreement, and he and the Company released and
discharged each other from all known and contingent liabilities and obligation. The Company
retired stock options held by Mr. Lichtenberger for nominal consideration.
Item 2.01 Completion of Acquisition or Disposition of Assets.
On
March 5, 2009, the Company and Four Rivers BioEnergy, Inc.
("Four Rivers") consummated the transactions contemplated by their
previously disclosed Asset Purchase Agreement, dated as of January 28, 2009. The Company sold to
Four Rivers its STT
®
reactors and STT
®
technology as well as its modular biodiesel production plant
equipment and related assets. The assets sold constituted substantially all of the assets of the
Company. The aggregate consideration paid by Four Rivers to the Company consisted of $2,792,000 in
cash, the assumption of certain of purchase orders and contracts, 1,200,000 shares of Four Rivers'
common stock and a warrant to purchase 200,000 shares of Four Rivers' common stock at an exercise
price of $8.00 per share with an expiration date of March 5, 2014. The warrant provides for
anti-dilution adjustment in limited circumstances and piggyback registration rights with respect to
the underlying shares of common stock.
Of the 1,200,000 shares of Four Rivers common stock issued to the Company, 300,000 will be held in
escrow solely to cover the exercise of certain Company warrants that are exercisable until January
12, 2012, which if not exercised will cause the shares to be returned to Four Rivers.
The shares of Four Rivers common stock and the Four Rivers warrant (including the underlying
shares) are subject to a 360 day holding requirement, after which the shares may be sold or
distributed.
The Asset Purchase Agreement and the transactions therein were approved by the holders of a
majority of the issued and outstanding shares of Company common stock at a duly noticed
stockholders meeting held on March 4, 2009.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers
At a duly noticed stockholders meeting held on March 4, 2009, the following directors were
re-elected to the Company's Board of Directors: G. A. Ben Binninger, Betsy Wood Knapp, David
Mandel and David Nazarian.
As discussed under Item 1.02 above, on March 5, 2009, in connection with the sale of assets
discussed under Item 2.01 above, the Company effected a Separation Agreement with Philip
Lichtenberger, Senior Vice President and Chief Operating Officer of the Company, pursuant to which
his Employment Agreement dated April 4, 2007 and his employment with the Company and its wholly
owned subsidiaries were terminated.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits
Exhibit
Number
99.1
Separation
Agreement dated as of February 27, 2009 by and among
Kreido Biofuels, Inc., Kreido Laboratories and Philip Lichtenberger
99.2
Asset Purchase Agreement dated as of January 28, 2009 by and among
Four Rivers BioEnergy, Inc., The Four Rivers BioEnergy Company, Inc.,
Kreido Biofuels, Inc. and Kreido Laboratories (incorporate by
reference to Exhibit 99.2 to Current Report on Form 8-K filed by the
Company on February 23, 2009, File No. 333-130606)
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Information included in this Form 8-K may contain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"). This information may involve
known and unknown risks, uncertainties and other factors which may cause the Company's actual
results, performance or achievements to be materially different from future results, performance or
achievements expressed or implied by any forward-looking statements. Forward-looking statements,
which involve assumptions and describe the Company's future plans, strategies and expectations, are
generally identifiable by use of the words "may," "will," "should," "expect," "anticipate,"
"estimate," "believe," "intend" or "project" or the negative of these words or other variations on
these words or comparable terminology. These forward-looking statements are based on assumptions
that may be incorrect, and there can be no assurance that any projections included in these
forward-looking statements will come to pass. The Company's actual results could differ materially
from those expressed or implied by the forward-looking statements as a result of various factors.
Except as required by applicable laws, the Company undertakes no obligation to update publicly any
forward-looking statements for any reason, even if new information becomes available or other
events occur in the future.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
KREIDO BIOFUELS, INC.
Dated: March 5, 2009
By:
G.A. Ben Binninger /s/
Name:
G.A. Ben Binninger
Its: Chief Executive Officer
EXHIBIT INDEX
Exhibit
Number
99.1
Separation Agreement dated as of February 27, 2009 by and among
Kreido Biofuels, Inc., Kreido Laboratories and Philip Lichtenberger
99.2
Asset Purchase Agreement dated as of January 28, 2009 by and among
Four Rivers BioEnergy, Inc., The Four Rivers BioEnergy Company, Inc.,
Kreido Biofuels, Inc. and Kreido Laboratories (incorporate by
reference to Exhibit 99.2 to Current Report on Form 8-K filed by the
Company on February 23, 2009, File No. 333-130606)